Home > Dermatology > EADV 2022 > Roflumilast 0.3% foam beneficial in various aspects of seborrheic dermatitis

Roflumilast 0.3% foam beneficial in various aspects of seborrheic dermatitis

Presented By
Prof. Andrew Blauvelt, Oregon Medical Research Center, OR, USA
Conference
EADV 2022
Trial
Phase 3, STRATUM
Encouraging results came from the phase 3 trial STRATUM on seborrheic dermatitis as over 80% reached the primary endpoint of clear or almost clear skin, according to the Investigator´s Global Assessment (IGA) at week 8. On top, also erythema and scaling were markedly improved. Due to positive results in phase 2, a 0.3% foam preparation of the PDE4-inhibitor roflumilast entered phase 3 in the STRATUM study (NCT04973228) on treatment for seborrheic dermatitis. After a 2:1 randomisation, patients received either the active drug foam once daily or a vehicle over 8 weeks. 457 participants were recruited, among them 7% aged 9–17, as the disease already may occur in pubescents. Participants all had IGA ≥3, equalling at least moderate disease and an affected body surface area ≤20%. Success, in terms of the primary endpoint, meant achieving an IGA of 0/1 correspondi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on